[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-372900-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-372900-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","evaluation-of-nanoencapsulated-bevacizumab-combined-with-paclitaxel-in-a-colorectal-cancer-xenograft-model","Evaluation of nanoencapsulated bevacizumab combined with paclitaxel in a colorectal cancer xenograft model","","Combination therapy using bevacizumab and paclitaxel (PTX) was investigated for synergistic antitumor performance in colorectal cancer. The study assessed nanoencapsulated bevacizumab (B-NPDEX) with PTX in a CRC xenograft mouse model, comparing free versus nanoencapsulated bevacizumab. Both regimens reduced tumor growth, metabolism, and weight, but PTX plus B-NP-DEX produced stronger effects, including lower VEGF and proliferation markers. PET imaging and biodistribution indicated markedly improved tumor targeting and a higher tumor-to-plasma ratio for nanoencapsulated bevacizumab, supporting further translational evaluation for safer, more effective antiangiogenic chemotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/evaluation-of-nanoencapsulated-bevacizumab-combined-with-paclitaxel-in-a-colorectal-cancer-xenograft-model/372900/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/evaluation-of-nanoencapsulated-bevacizumab-combined-with-paclitaxel-in-a-colorectal-cancer-xenograft-model/372900.png","ImageObject",300,407,{"name":42,"@type":43},"MrHarris58","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study?","Question",{"text":63,"@type":64},"To evaluate whether nanoencapsulated bevacizumab (B-NPDEX) combined with paclitaxel provides benefits as part of a systemic regimen for colorectal cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were bevacizumab and paclitaxel delivered in the experiments?",{"text":68,"@type":64},"Bevacizumab was administered either as an aqueous solution or nanoencapsulated in albumin-based nanoparticles coated with dextran, and combined with paclitaxel via intravenous administration in a CRC xenograft model.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supported improved tumor targeting by nanoencapsulated bevacizumab?",{"text":72,"@type":64},"PET imaging and biodistribution showed an approximately 8-fold higher tumor-to-plasma ratio for nanoencapsulated bevacizumab, consistent with enhanced permeability and retention and better targeting.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},372900,1790392961,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Drug Delivery and Translational Research (2026) 16:2194–2206  \n[https://doi.org/10.1007/s13346-025-01941-6](https://doi.org/10.1007/s13346-025-01941-6)  \nORIGINAL ARTICLE  \nEvaluation of nanoencapsulated bevacizumab combined with paclitaxel in a colorectal cancer xenograft model  \nCristina Pangua1 · Socorro Espuelas1,6 · Jon Ander Simón3 · María Collantes4,6 · Iván Peñuelas4,5,6 · Alfonso Calvo2,6 · Juan M. Irache1,6  \nAccepted: 26 July 2025 / Published online: 14 August 2025 © The Author(s) 2025  \nAbstract  \nThe combination of bevacizumab and paclitaxel (PTX) has exhibited synergistic antitumor effects in different types of solid cancer tumors probably due to a potential increase of intratumoral PTX facilitated by the action of the antiangiogenic agent bevacizumab. The aim of this study was to evaluate the benefits of using nanoencapsulated bevacizumab (B-NPDEX) in combination with paclitaxel as part of a systemic therapeutic regimen for colorectal cancer (CRC) . For this purpose, bevacizumab (either as aqueous solution or nanoencapsulated in albumin based-nanoparticles coated with dextran) in combination with paclitaxel were intravenously administered and evaluated in a xenograft mouse model of CRC. Both treatments (free and nanoencapsulated bevacizumab and PTX) significantly reduced tumor growth, metabolic activity, and weight, extending tumor-doubling time by approximately 5 days when compared with control animals (receiving saline) . However, animals treated with the combination between PTX and B-NP-DEX showed enhanced antitumor effects than the conventional treatment with free bevacizumab, including a greater reduction in tumor growth rate, VEGF levels, and proliferation markers. PET imaging and biodistribution analysis revealed an 8-fold higher tumor-to-plasma ratio for the nanoencapsulated bevacizumab, suggesting improved tumor targeting via the enhanced permeability and retention effect. These findings support the potential of nanoparticle-based delivery systems to increase therapeutic efficacy while potentially reducing systemic toxicity, warranting further investigation into their role in optimizing antiangiogenic chemotherapy.  \nKeywords Bevacizumab · Paclitaxel · Albumin nanoparticles · Dextran · Colorectal cancer  \n􀀍 Juan M. Irache [jmirache@unav.es](jmirache@unav.es)  \n1 Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, NANO-VAC Research Group, University of Navarra, Pamplona 31008, Spain  \n2 Program in Solid Tumors, CIMA of the University of Navarra, Pamplona 31008, Spain  \n3 Department of Chemistry, University of Navarra, Pamplona 31008, Spain  \n4 Radiopharmacy Unit, Clinica Universidad de Navarra, Pamplona 31008, Spain  \n5 Translational Molecular Imaging Unit (UNIMTRA), Department of Nuclear Medicine, Clinica Universidad de Navarra, Pamplona 31008, Spain  \n6 Institute for Health Research (IdiSNA), Pamplona 31008, Spain  \nIntroduction  \nBevacizumab belongs to a relatively newer class of cancer therapeutics known as angiogenesis inhibitors. As a monoclonal antibody (mAb), bevacizumab selectively targetsand neutralizes vascular endothelial growth factor (VEGF), a crucial protein involved in promoting new blood vessels formation that supports tumor growth and metastasis [1]. By inhibiting angiogenesis, bevacizumab effectively deprives tumors oftheir blood supply, hindering their expansion and ultimately leading to regression [2, 3] .  \nThe clinical history of bevacizumab in the past 20 years has raised concerns about its safety. Several adverse effects have been reported, including hypertension, gastrointestinal perforations, and even therapy resistance, all of which limit the effectiveness of bevacizumab [4–6] . Despite these facts, bevacizumab is still a leading treatment option. Its antiangiogenic effect has been reported to contribute to the normalization of tumor vascularization, enhancing the  \nefficacy of the chemotherapeutic agents administered concurrently [7] . In this context, th","cbCaipyjzgjIvuu2","https://ap.wps.com/l/cbCaipyjzgjIvuu2","pdf",1287010,13,"English","# Abstract\n# Introduction\n## Bevacizumab: angiogenesis inhibition and clinical concerns\n## Paclitaxel: mechanism and formulation-related limitations\n## Rationale for combining bevacizumab with paclitaxel","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To evaluate whether nanoencapsulated bevacizumab (B-NPDEX) combined with paclitaxel provides benefits as part of a systemic regimen for colorectal cancer.\"},{\"question\":\"How were bevacizumab and paclitaxel delivered in the experiments?\",\"answer\":\"Bevacizumab was administered either as an aqueous solution or nanoencapsulated in albumin-based nanoparticles coated with dextran, and combined with paclitaxel via intravenous administration in a CRC xenograft model.\"},{\"question\":\"What evidence supported improved tumor targeting by nanoencapsulated bevacizumab?\",\"answer\":\"PET imaging and biodistribution showed an approximately 8-fold higher tumor-to-plasma ratio for nanoencapsulated bevacizumab, consistent with enhanced permeability and retention and better targeting.\"}]","Evaluation of nanoencapsulated bevacizumab combined with paclitaxel in a colorectal cancer xenograft model | PDF",1790195695,33]